NEW YORK (GenomeWeb News) – UK Contract research organization Domainex and Sigma-Aldrich today announced a collaboration to develop tools for epigenetic research.
Under the deal, Domainex will use its proprietary Combinatorial Domain Hunting technology to clone and express proteins to build biochemical assays for target enzymes. The technology, the company said in a statement, allows researchers to clone and express challenging proteins, producing soluble domains of proteins with key roles in epigenetics.
Sigma-Aldrich will use the proteins as antigens to raise specific monoclonal antibodies. It will also distribute the assays and monoclonal antibodies, which scientists can use to identify target proteins, and then characterize and study their functions in detail.
Funding from the UK's Technology Strategy Board will support the work. Financial and other terms were not disclosed.